FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WITTY ANDREW				2. Issuer Name and Ticker or Trading Symbol G1 Therapeutics, Inc. [ GTHX ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								
			٦	OT Therapeutes, Inc. [ GIIIA ]								X	Director		10% Owne		ner		
				L										Officer below)	(give title		Other (sp	pecify	
(Last) (First) (Middle) C/O G1 THERAPEUTICS, 79 TW ALEXANDER DR.					3. Date of Earliest Transaction (Month/Day/Year) 06/07/2018									Delowy			Belowy		
4501 RE	SEARCH C	COMMONS, SU	ITE 100																
					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	N.C.I.I													X	Form fi	led by One	Repo	rting Person	
RESEAF TRIANC PARK	_	С	27709													led by More		One Report	- 1
(City)	(S	tate)	(Zip)																
		Tab	le I - Non	ı-Deriv	ative	e Se	curities	s Ac	quired, D	ispos	sed o	f, or Be	nefici	ally O	wned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/E				Executio		Date,	Code (Ins	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)				4 and Securition Beneficition Owned I		es Form ally (D) ( Following (I) (I	Form: (D) or	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code V	Ar	mount	(A) o	(A) or (D) Prio		Reported Fransact Instr. 3 a	tion(s)		(	Instr. 4)	
		7							uired, Dis , options						ned			,	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution E if any (Month/Day	Date, T	Code (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Der Sec	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expir Date	ration	Title	Amou or Numb of Shares	er					
Stock Option (right to buy)	\$38.39	06/07/2018			A		10,000		(1)	06/07	7/2028	Common Stock	10,00	0 \$	60.00	10,000		D	

## **Explanation of Responses:**

1. The shares underlying this option will vest in their entirety twelve months after June 7, 2018, subject to the Reporting Person's continued service as a director.

## Remarks:

/s/ Megan Gates, attorney-in-

06/11/2018

Date

<u>fact</u>

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.